Diagnosing Epilepsy & Seizure Disorders in Children | NYU Langone Health
Experts at Hassenfeld Children’s Hospital at NYU Langone use exams, tests, and EEG to diagnose epilepsy and seizure disorders.
chna-winthrop-university-hospital-2016-final.pdf
... % 1 http://factfinder.census.gov/faces/nav/jsf/pages/community_facts.xhtml 5 from 2013. Race ... , Tri Care Systems DBA LIAAC 2 http://factfinder.census.gov/faces/tableservices/jsf/pages ...
Pediatric Congenital Heart Program | NYU Langone Health
The Pediatric Congenital Heart Program at Hassenfeld Children’s Hospital offers innovative care for people with congenital heart conditions.
Obstetrics & Gynecology | NYU Langone Health
At NYU Langone, our obstetrician–gynecologists provide experienced and compassionate care to people of all ages and gender identities.
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD
The proposed study is a double-blind, 2-group randomized controlled trial designed to contrast acute and persisting effects of topiramate to those of placebo treatment in a sample of 150 participants with moderate to severe AUD comorbid with PTSD/subthreshold PTSD, and to evaluate the moderating effect of rs2832407 genotype on medication effects. Participants will be randomized in a 2:1 ratio to topiramate vs. placebo. Drug will be titrated to a maximum dose of 200 mg over 8 weeks, continued for 4 more weeks for a total of 12 weeks of treatment, and tapered over a 2-week period. We propose an integrative translational focus on alterations in excitatory and inhibitory signaling, focusing on GABA and glutamate and related circuitry, to model the neurobiology of AUD comorbid with PTSD/subthreshold PTSD and the mitigating effects of topiramate. We will study the behavioral, genetic, and plasma biomarker effects of topiramate vs. placebo in 150 participants with co-occurring AUD and PTSD/subthreshold and ascertain multi-modal imaging markers including structural MRI, task-based fMRI, and TMS evoked potentials in EEG. Imaging markers will be used to characterize excitatory and inhibitory circuits in the clinical trial participants with AUD+PTSD/subthreshold to determine predictors and mechanisms of topiramate vs. placebo treatment outcomes. Clinical interviews will be audio- taped to ensure clinical adherence and conduct interrater reliability. De-identified audio recordings of participants who consent to participate in the voicemarkers analysis will be encrypted and sent via secure sites for analysis. This project will advance our knowledge of personalized medicine for AUD comorbid with PTSD/subthreshold, with particular emphasis on understanding the mechanisms that account for the high variability in treatment outcomes for this comorbidity, how treatments like TPM are effective for certain individuals, and how best to identify those most likely to respond to TPM.
THE PROSPECTIVE NATURAL HISTORY OF FAMILIAL DYSAUTONOMIA
Our ultimate goal is to develop new treatments for patients with familial dysautonomia (FD, OMIM 223900). We also want to learn which specific nerve populations are affected by the disease-causing mutation, whether these features are progressive, and how best to measure them in clinical trials. FD is caused by a founder mutation in the IKBKAP gene that is carried by 1:30 people of European Jewish ancestry. Over 99% of affected patients have two copies of the identical founder mutation. This affects the development of the sensory nervous system, which relays information to the brain. FD is both developmental and progressive. Current drug treatments are supportive and none specifically target the on-going neurological decline. Partnership between academic centers, advocacy groups and federal agencies has allowed the creation of a pipeline for drug development and an infrastructure for translational research. The first aim of this project will be to enroll patients with FD from around the world in a non-interventional natural history study. We will score the severity of their clinical features and follow how they evolve over time. The natural history will focus on establishing disease-specific milestones to use as outcome measures in future clinical trials. We will find ways to measure the progressive neurological aspects of the disease including blindness and gait ataxia, which are intrinsically related and most devastating to the patient’s quality of life overtime. We will also explore other potential biomarkers that quantify renal, cardiovascular, respiratory, orthopedic and cognitive aspects of the disease, which will help us monitor adverse events. The second aim of this project will address one of the most intriguing questions about the disease; why some patients are more severely affected than others. The study will include genomic sequencing from patients with FD, to find specific modifier genes that influence the severity of traits as possible targets for future drug development. Some of these genes may be important in the general population, but discovering them could be easier in FD patients due to >99% being homozygous for the founder mutation.
sustainability-report.pdf
... . Our longstanding and robust energy management program focuses on resilient infrastructure design ... focus on creating consistent, institution-wide policies and programs that drive optimal and sustainable ...
Rusk Rehabilitation | NYU Langone Health
At NYU Langone’s Rusk Rehabilitation, you receive care that meets your physical, social, emotional, cognitive, and psychological needs.
Our Dance Medicine Team | NYU Langone Health
Experts at NYU Langone’s Harkness Center for Dance Injuries aim to improve the delivery of dance medicine.
Voice, Swallowing & Airway Conditions We Treat | NYU Langone Health
At NYU Langone’s Voice Center, we are experts in a range of conditions that affect your ability to speak, swallow, and breathe.